Based on results from the ASSET-IT clinical trial, administration of tirofiban within 1 hour of I.V. thrombolysis correlates with better odds of excellent functional outcome in stroke patients. The multicenter, Phase III study was conducted in China and included patients with acute ischemic noncardioembolic stroke who received thrombolysis no more than 4.5 hours after time last known well. After I.V. thrombolysis, participants were randomly assigned either to a 24-hour infusion of the antiplatelet agent tirofiban or to placebo. The primary efficacy outcome, excellent functional outcome based on modified Rankin scale (mRS) score, was evaluated at 90 days. Among 414 patients in the tirofiban group, 65.9% achieved a score of 0 or 1 on the mRS compared with 54.9% of 418 patients in the control arm. In terms of safety, symptomatic intracranial hemorrhage within 36 hours affected 1.7% of tirofiban recipients but 0% of controls; while 90-day mortality was documented in 4.1% vs. 3.8% of participants, respectively.